
Future advances in childhood cancer treatment will zzso on developing zzso new drug development pathways that build on current knowledge of zzso zzso however, we need to address major barriers to zzso new drugs for clinical evaluation in childhood zzso 

Through legislative change, substantial incentives to the pharmaceutical industry to invest in the zzso diseases, such as childhood zzso have encouraged greater engagement with zzso zzso drug development zzso Disappointingly, this has not translated into zzso drug zzso Adult zzso drug development will continue to dominate until zzso approaches zzso are specific challenges to zzso early drug development trials in children with incurable zzso The balance between risk and benefit for a child participating in trials wherein the chance of clinical benefit is indeterminate has the potential for unrealistic optimism by both physicians and zzso zzso innovative trial designs that assess safety and maximize information on potential efficacy from small patient numbers are zzso 

International collaboration in early phase trial zzso addresses these zzso Academic networks concentrating early phase trials expertise and delivery of innovative trial designs will maximize appropriate selection of drugs that can translate into therapeutic advantage when incorporated into standard zzso 

